by John Conrad | Mar 9, 2020 | COVID, Member News
AbbVie (NYSE:ABBV) today confirmed the company’s activities in the fight to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Kaletra/Aluvia (lopinavir/ritonavir) to determine its efficacy in the treatment...
by John Conrad | Mar 9, 2020 | COVID, iBIO News
The Coronavirus is a serious global public health threat with information rapidly evolving. Innovative Life Sciences Companies are ramping up efforts to study the virus and develop solutions to prevent, diagnose and treat this deadly infectious disease. Companies are...
by John Conrad | Mar 6, 2020 | COVID
Baxter has committed resources to relief organizations and Baxter teams are providing support to hospitals and healthcare providers who are on the frontlines of patient care. Donations for Humanitarian Relief: Through the Baxter International Foundation, we’ve...
by John Conrad | Mar 5, 2020 | COVID
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with...
by John Conrad | Mar 2, 2020 | COVID
Drugs previously in development for SARS could be effective for COVID-19 A potential drug target has been identified in a newly mapped protein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19). The structure was solved by a team including the...
by John Conrad | Feb 27, 2020 | COVID
As one of the first pharmaceutical companies to respond to the emerging novel coronavirus (COVID-19) crisis, in late January, AbbVie donated a supply of Kaletra/Aluvia (lopinavir/ritonavir) to the Chinese health authorities for use as an experimental treatment option....
